FTD is a modest positive for pipeline de-risking but does not alter the binary nature of Phase 3 readouts. Monitor for initiation of the planned pancreatic Phase 3 trial and any subsequent FDA feedback that could accelerate timelines.
Price Chart
Executive Summary
Erasca announced that the FDA granted Fast Track Designation (FTD) to ERAS-0015 for the treatment of metastatic pancreatic adenocarcinoma. FTD may expedite development and review but does not change approval standards or guarantee a faster timeline. This is a modest regulatory catalyst for a pipeline asset, not a fundamental change in the company's outlook.
Key Facts
- FDA granted Fast Track Designation to ERAS-0015 for metastatic pancreatic adenocarcinoma
- FTD may enable more frequent FDA interactions and eligibility for accelerated approval, priority review, and rolling review
- FTD does not change approval standards and the FDA may later revoke the designation
- Company plans to initiate a Phase 3 trial in pancreatic cancer and two potentially registration-enabling trials in lung cancer
Financial Impact
No financial figures disclosed; FTD is a regulatory milestone with no direct revenue or cost impact reported
Risk Factors
- FTD does not guarantee faster approval or change the standard for regulatory approval
- ERAS-0015 may fail to demonstrate sufficient efficacy or safety in clinical trials
- Company may prioritize resources on this program at the expense of other candidates
- FDA may later determine the product no longer meets FTD qualification criteria
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-361895 |
| Document: 0001193125-26-361895-index.html | 0001193125-26-361895 |
| Document: 0001193125-26-361895.txt | 0001193125-26-361895 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | 8-K | $13.39 | awaiting T+60 | — | $14.39 (+7.47%) |
Aug 24, 2026 9w ago | 8-K | $17.60 | awaiting T+60 | — | $14.39 (−18.24%) |
Aug 17, 2026 10w ago | 144 | $18.28 | awaiting T+60 | — | $14.39 (−21.28%) |
Aug 13, 2026 10w ago | Institutional Cluster | $17.86 | awaiting T+60 | — | $14.39 (−19.43%) |
Aug 12, 2026 10w ago | 3 | $17.86 | awaiting T+60 | — | $14.39 (−19.43%) |
Aug 11, 2026 10w ago | Press Release | $18.58 | awaiting T+60 | — | $14.39 (−22.55%) |
Jul 14, 2026 14w ago | 8-K | $21.26 $15.46 | ▼ −27.28% | ▼ −29.81% | $14.39 (−32.31%) |
Jul 14, 2026 14w ago | 424B5 | $21.26 $15.46 | ▼ −27.28% | ▼ −29.81% | $14.39 (−32.31%) |
Jul 13, 2026 14w ago | Press Release | $19.50 $14.12 | ▲ +27.59% | ▲ +30.97% | $14.39 (+26.21%) |
Jul 13, 2026 15w ago | Press Release | $19.50 $14.12 | ▼ −27.59% | ▼ −30.97% | $14.39 (−26.21%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers